Kate M Mitchell1, Dobromir Dimitrov2, Romain Silhol3, Lily Geidelberg4, Mia Moore2, Albert Liu5, Chris Beyrer6, Kenneth H Mayer7, Stefan Baral6, Marie-Claude Boily3. 1. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. Electronic address: kate.mitchell@imperial.ac.uk. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. 4. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK; Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK. 5. Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Bridge HIV, Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 7. The Fenway Institute, Fenway Health, Boston, MA, USA; Harvard Medical School and TC School of Public Health, Boston, MA, USA.
Abstract
BACKGROUND: During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM. METHODS: We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions. FINDINGS: A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]). INTERPRETATION: Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships. FUNDING: National Institutes of Health.
BACKGROUND: During the COVID-19 pandemic, men who have sex with men (MSM) in the USA have reported similar or fewer sexual partners and reduced HIV testing and care access compared with before the pandemic. Pre-exposure prophylaxis (PrEP) use has also declined. We aimed to quantify the potential effect of COVID-19 on HIV incidence and HIV-related mortality among US MSM. METHODS: We used a calibrated, deterministic, compartmental HIV transmission model for MSM in Baltimore (MD, USA) and available data on COVID-19-related disruptions to HIV services to predict effects of reductions in sexual partners (0%, 25%, 50%), condom use (5%), HIV testing (20%), viral suppression (10%), PrEP initiations (72%), PrEP adherence (9%), and antiretroviral therapy (ART) initiations (50%). In our main analysis, we modelled disruptions due to COVID-19 starting Jan 1, 2020, and lasting 6 months. We estimated the median change in cumulative new HIV infections and HIV-related deaths among MSM over 1 and 5 years, compared with a base case scenario without COVID-19-related disruptions. FINDINGS: A 25% reduction in sexual partners for 6 months among MSM in Baltimore, without HIV service changes, could reduce new HIV infections by median 12·2% (95% credible interval 11·7 to 12·8) over 1 year and median 3·0% (2·6 to 3·4) over 5 years. In the absence of changes in sexual behaviour, the 6-month estimated reductions in condom use, HIV testing, viral suppression, PrEP initiations, PrEP adherence, and ART initiations combined are predicted to increase new HIV infections by median 10·5% (5·8 to 16·5) over 1 year, and by median 3·5% (2·1 to 5·4) over 5 years. Disruptions to ART initiations and viral suppression are estimated to substantially increase HIV-related deaths (ART initiations by median 1·7% [0·8 to 3·2], viral suppression by median 9·5% [5·2 to 15·9]) over 1 year, with smaller proportional increases over 5 years. The other individual disruptions (to HIV testing, PrEP and condom use, PrEP initiation, and partner numbers) were estimated to have little effect on HIV-related deaths (<1% change over 1 or 5 years). A 25% reduction in sexual partnerships is estimated to offset the effect of the combined service disruptions on new HIV infections (change over 1 year: median -3·9% [-7·4 to 1·0]; over 5 years: median 0·0% [-0·9 to 1·4]), but not on HIV deaths (change over 1 year: 11·0% [6·2 to 17·7]; over 5 years: 2·6% [1·5 to 4·3]). INTERPRETATION: Maintaining access to ART and adherence support is of the utmost importance to maintain viral suppression and minimise excess HIV-related mortality due to COVID-19 restrictions in the USA, even if disruptions to services are accompanied by reductions in sexual partnerships. FUNDING: National Institutes of Health.
Authors: Kate M Mitchell; Brooke Hoots; Dobromir Dimitrov; Danielle German; Colin Flynn; Jason E Farley; Marcy Gelman; James P Hughes; Deborah Donnell; Adeola Adeyeye; Robert H Remien; Chris Beyrer; Gabriela Paz-Bailey; Marie-Claude Boily Journal: J Int AIDS Soc Date: 2019-03 Impact factor: 5.396
Authors: Samuel M Jenness; Adrien Le Guillou; Christina Chandra; Laura M Mann; Travis Sanchez; Daniel Westreich; Julia L Marcus Journal: J Infect Dis Date: 2021-03-29 Impact factor: 5.226
Authors: Glenn-Milo Santos; Benjamin Ackerman; Amrita Rao; Sara Wallach; George Ayala; Erik Lamontage; Alex Garner; Ian W Holloway; Sonya Arreola; Vince Silenzio; Susanne Strömdahl; Louis Yu; Carol Strong; Tyler Adamson; Anna Yakusik; Tran Thu Doan; Poyao Huang; Damiano Cerasuolo; Amie Bishop; Teymur Noori; Anastasia Pharris; Max Aung; Masoud Dara; Ssu Yu Chung; Marguerite Hanley; Stefan Baral; Chris Beyrer; Sean Howell Journal: AIDS Behav Date: 2021-02
Authors: Britta L Jewell; Edinah Mudimu; John Stover; Debra Ten Brink; Andrew N Phillips; Jennifer A Smith; Rowan Martin-Hughes; Yu Teng; Robert Glaubius; Severin Guy Mahiane; Loveleen Bansi-Matharu; Isaac Taramusi; Newton Chagoma; Michelle Morrison; Meg Doherty; Kimberly Marsh; Anna Bershteyn; Timothy B Hallett; Sherrie L Kelly Journal: Lancet HIV Date: 2020-08-06 Impact factor: 12.767
Authors: Rob Stephenson; Tanaka M D Chavanduka; Matthew T Rosso; Stephen P Sullivan; Renée A Pitter; Alexis S Hunter; Erin Rogers Journal: AIDS Behav Date: 2021-01
Authors: Joshua A Barocas; Alexandra Savinkina; Sara Lodi; Rachel L Epstein; Tara C Bouton; Heather Sperring; Heather E Hsu; Karen R Jacobson; Elissa M Schechter-Perkins; Benjamin P Linas; Laura F White Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Brian R Wood; Kristine F Lan; Yuan Tao; Eric Y Mose; Erin Aas; Jehan Z Budak; Shireesha Dhanireddy; H Nina Kim Journal: Open Forum Infect Dis Date: 2021-09-23 Impact factor: 3.835
Authors: Eugenia Quiros-Roldan; Ilaria Izzo; Canio Carriero; Melania Degli Antoni; Samuele Storti; Giorgio Tiecco; Giulia Gardini; Emanuele Focà; Francesco Castelli Journal: J Public Health Res Date: 2021-09-24
Authors: Jamison Norwood; Asghar Kheshti; Bryan E Shepherd; Peter F Rebeiro; Aimalohi Ahonkhai; Sean Kelly; Celestine Wanjalla Journal: AIDS Behav Date: 2022-02-23
Authors: Mary Jo Trepka; Melissa K Ward; Robert A Ladner; Diana M Sheehan; Tan Li; Cynthia Ibarra; Semiu O Gbadamosi; Gladys E Ibañez; Michele Jean-Gilles Journal: J Int Assoc Provid AIDS Care Date: 2022 Jan-Dec
Authors: Ethan Moitra; Jun Tao; Joseph Olsen; Riley D Shearer; Brian R Wood; Andrew M Busch; Andrea LaPlante; Jason V Baker; Philip A Chan Journal: Lancet Reg Health Am Date: 2021-12-23
Authors: Tyler Adamson; Marguerite Hanley; Stefan Baral; Chris Beyrer; Sara Wallach; Sean Howell Journal: BMJ Open Date: 2022-04-12 Impact factor: 2.692